Fmr LLC lessened its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 3.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,743,012 shares of the company’s stock after selling 53,400 shares during the period. Fmr LLC owned 7.38% of Axsome Therapeutics worth $9,587,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. bought a new stake in Axsome Therapeutics in the 1st quarter valued at $121,000. SG Americas Securities LLC bought a new stake in Axsome Therapeutics in the 1st quarter valued at $139,000. LMR Partners LLP bought a new stake in Axsome Therapeutics in the 2nd quarter valued at $206,000. Finally, Sphera Funds Management LTD. raised its stake in Axsome Therapeutics by 24.9% in the 2nd quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after acquiring an additional 100,000 shares during the period. Institutional investors and hedge funds own 27.13% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Axsome Therapeutics, Inc. (AXSM) Shares Sold by Fmr LLC” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/10/31/axsome-therapeutics-inc-axsm-shares-sold-by-fmr-llc.html.

Axsome Therapeutics, Inc. (AXSM) opened at 4.80 on Tuesday. The firm’s market capitalization is $113.33 million. The firm has a 50-day moving average price of $5.27 and a 200-day moving average price of $4.92. Axsome Therapeutics, Inc. has a one year low of $3.53 and a one year high of $7.75.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Wednesday, August 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.01. Analysts expect that Axsome Therapeutics, Inc. will post ($1.38) EPS for the current year.

AXSM has been the topic of a number of research analyst reports. Zacks Investment Research cut Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $31.00 price target (up previously from $28.00) on shares of Axsome Therapeutics in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Axsome Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $16.85.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.